Wu, JN,
Al-Zahrani, A,
Beylerli, O,
Sufianov, R,
Talybov, R,
Meshcheryakova, S,
Sufianova, G,
Gareev, I,
Sufianov, A (2022) Central Register of
Controlled Trials, and Web of Science database and obtained different sets of data
Malieyskiy, O.,
Mykola, A.,
Nataliya, Z.,
Bolshova, E.V.,
Senatorova, G.,
Oroszlan, G.,
Skorodok, J.,
Peterkova, V.,
Nataliya, C.,
Sorokman, T.,
Yang, S.,
Lee, J.E.,
Muzsnai, A.,
Hwang, J.S.,
Lee, S.Y.,
Choi, Y.J.,
Ji, H.J.,
Woo, J.,
Sung, Y.C. (2018) ®, in pediatric patients with GHD. A
randomized, open-label, active-
controlled, parallel study was conducted at 27
Zhao, S.,
Sufianova, G.,
Shapkin, A.,
Mashkin, A.,
Meshcheryakova, S.,
Han, DY (2022) at the cervical (C3-C5) and lower thoracic (Th9-Th10) levels.
Results: In all patients, on the 5th day of
trialAKHMADIEV, N.S.,
AKHMETOVA, V.R.,
IBRAGIMOV, A.G.,
GALIMOVA, A.M.,
GALIMOVA, R.A.,
AGLETDINOV, E.F.,
KATAEV, V.A.,
KHAIRULLINA, V.R. (2019) ), a number of preclinical
trials has been conducted Methods: 2D and 3D structures
Han, Dayong,
Teng, Lei,
Wang, Xiaoxiong,
Zhen, Yunbo,
Chen, Xiaofeng,
Yang, Mingchun,
Gao, Ming,
Yang, Guang,
Han, Mingyang,
Wang, Ligang,
Xu, Jiajun,
Li, Yue,
Shumadalova, Alina,
Zhao, Shiguang (2022) , and the dose recommended for a phase II
trial is 1.5 mg. Copyright © 2022 Han, Teng, Wang, Zhen, Chen, Yang